| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 56 | 2022 | 708 | 6.360 |
Why?
|
| Depressive Disorder | 12 | 2017 | 557 | 2.170 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 666 | 1.580 |
Why?
|
| Cognition Disorders | 9 | 2022 | 786 | 1.440 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2018 | 901 | 1.060 |
Why?
|
| Depression | 18 | 2020 | 1715 | 1.000 |
Why?
|
| Anxiety | 13 | 2019 | 1179 | 0.950 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2021 | 8 | 0.840 |
Why?
|
| Mental Disorders | 6 | 2016 | 862 | 0.820 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 604 | 0.740 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 264 | 0.710 |
Why?
|
| Dementia | 4 | 2014 | 453 | 0.690 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 348 | 0.630 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 333 | 0.580 |
Why?
|
| Dystonia | 2 | 2020 | 163 | 0.560 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 147 | 0.550 |
Why?
|
| Panic Disorder | 2 | 2011 | 46 | 0.460 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 441 | 0.460 |
Why?
|
| Torticollis | 3 | 2021 | 72 | 0.460 |
Why?
|
| Comorbidity | 11 | 2020 | 2352 | 0.450 |
Why?
|
| Delusions | 2 | 2012 | 21 | 0.440 |
Why?
|
| Veterans | 5 | 2020 | 1641 | 0.440 |
Why?
|
| Hallucinations | 2 | 2012 | 35 | 0.440 |
Why?
|
| Illusions | 1 | 2012 | 10 | 0.420 |
Why?
|
| Health Services | 1 | 2012 | 105 | 0.420 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 5687 | 0.420 |
Why?
|
| Drug Utilization | 1 | 2013 | 179 | 0.410 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 349 | 0.400 |
Why?
|
| Disclosure | 1 | 2013 | 181 | 0.400 |
Why?
|
| Nootropic Agents | 2 | 2009 | 33 | 0.400 |
Why?
|
| Family Health | 3 | 2011 | 325 | 0.400 |
Why?
|
| Health Status | 2 | 2012 | 590 | 0.390 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 33 | 0.380 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 72 | 0.360 |
Why?
|
| Propylamines | 1 | 2009 | 12 | 0.340 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 32 | 0.340 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 81 | 0.320 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2014 | 854 | 0.310 |
Why?
|
| Prevalence | 11 | 2020 | 3260 | 0.300 |
Why?
|
| Humans | 73 | 2022 | 261506 | 0.290 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2006 | 110 | 0.290 |
Why?
|
| Aged | 36 | 2020 | 70117 | 0.290 |
Why?
|
| Middle Aged | 40 | 2020 | 86204 | 0.280 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 95 | 0.270 |
Why?
|
| Male | 46 | 2020 | 123000 | 0.260 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 4320 | 0.250 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2020 | 231 | 0.250 |
Why?
|
| Psychometrics | 6 | 2013 | 937 | 0.250 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2003 | 2 | 0.240 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 21 | 0.230 |
Why?
|
| Indans | 1 | 2004 | 68 | 0.230 |
Why?
|
| Mental Health Services | 3 | 2015 | 227 | 0.230 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 605 | 0.220 |
Why?
|
| HIV Infections | 1 | 2015 | 2134 | 0.210 |
Why?
|
| Female | 43 | 2020 | 141928 | 0.210 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 4314 | 0.210 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 29902 | 0.200 |
Why?
|
| Alzheimer Disease | 4 | 2015 | 855 | 0.200 |
Why?
|
| Neuropsychological Tests | 7 | 2013 | 1178 | 0.190 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.180 |
Why?
|
| Unconsciousness | 1 | 2019 | 21 | 0.180 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.180 |
Why?
|
| Dreams | 1 | 2019 | 28 | 0.170 |
Why?
|
| Tremor | 1 | 2020 | 128 | 0.170 |
Why?
|
| Internationality | 1 | 2020 | 208 | 0.170 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 133 | 0.170 |
Why?
|
| Sleep | 1 | 2021 | 413 | 0.160 |
Why?
|
| Piperidines | 1 | 2004 | 1035 | 0.160 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 418 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 552 | 0.160 |
Why?
|
| Interview, Psychological | 1 | 2018 | 98 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 134 | 0.160 |
Why?
|
| Hippocampus | 1 | 2003 | 915 | 0.150 |
Why?
|
| Brain Concussion | 1 | 2019 | 194 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 164 | 0.150 |
Why?
|
| Public Housing | 1 | 2016 | 14 | 0.140 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 524 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 1303 | 0.130 |
Why?
|
| Adult | 22 | 2021 | 77950 | 0.130 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 207 | 0.130 |
Why?
|
| Age of Onset | 6 | 2014 | 827 | 0.130 |
Why?
|
| Apathy | 1 | 2015 | 19 | 0.130 |
Why?
|
| Phenotype | 3 | 2021 | 6295 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 250 | 0.130 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 367 | 0.130 |
Why?
|
| Psychiatry | 1 | 2019 | 307 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2015 | 2803 | 0.120 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 20 | 0.120 |
Why?
|
| Disabled Persons | 1 | 2015 | 121 | 0.120 |
Why?
|
| Fatigue | 3 | 2010 | 1239 | 0.120 |
Why?
|
| Heterozygote | 3 | 2014 | 1020 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 313 | 0.110 |
Why?
|
| Role | 1 | 2013 | 48 | 0.110 |
Why?
|
| Mental Health | 2 | 2014 | 415 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 5539 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 548 | 0.110 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 5 | 0.100 |
Why?
|
| ROC Curve | 2 | 2020 | 1183 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 294 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2011 | 38 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 369 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2016 | 2307 | 0.100 |
Why?
|
| Mass Screening | 1 | 2020 | 1509 | 0.100 |
Why?
|
| Independent Living | 1 | 2012 | 73 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 298 | 0.100 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 47 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2011 | 2316 | 0.100 |
Why?
|
| Memory Disorders | 2 | 2004 | 295 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2013 | 298 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 332 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 556 | 0.100 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 31 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 179 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 63 | 0.090 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 22 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2010 | 133 | 0.090 |
Why?
|
| Societies, Scientific | 1 | 2010 | 74 | 0.090 |
Why?
|
| alpha-Synuclein | 3 | 2005 | 118 | 0.090 |
Why?
|
| Research Design | 2 | 2015 | 1544 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 126 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 769 | 0.090 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 16 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2015 | 787 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1148 | 0.080 |
Why?
|
| Neoplasms | 1 | 2015 | 15193 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1491 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 918 | 0.080 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 9 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 131 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2008 | 41 | 0.080 |
Why?
|
| Genetic Counseling | 1 | 2010 | 380 | 0.080 |
Why?
|
| Lewy Body Disease | 2 | 2004 | 20 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 58 | 0.080 |
Why?
|
| United States | 6 | 2019 | 15433 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 383 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 860 | 0.080 |
Why?
|
| Movement Disorders | 1 | 2010 | 232 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 229 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.070 |
Why?
|
| Education | 1 | 2007 | 112 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2013 | 1171 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 677 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 348 | 0.070 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 14 | 0.070 |
Why?
|
| MEDLINE | 1 | 2006 | 36 | 0.070 |
Why?
|
| Stroke | 1 | 2014 | 1144 | 0.070 |
Why?
|
| Mutation | 4 | 2010 | 15179 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 151 | 0.070 |
Why?
|
| Motivation | 1 | 2008 | 499 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 376 | 0.060 |
Why?
|
| Quality of Life | 5 | 2021 | 4532 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 562 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 65 | 0.060 |
Why?
|
| Mammillary Bodies | 1 | 2003 | 3 | 0.060 |
Why?
|
| Diencephalon | 1 | 2003 | 14 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 215 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 2218 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 589 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2315 | 0.060 |
Why?
|
| Consensus | 1 | 2007 | 978 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 4744 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 344 | 0.050 |
Why?
|
| Young Adult | 5 | 2020 | 21445 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 1099 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 89 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 1972 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 135 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5542 | 0.050 |
Why?
|
| Synucleins | 3 | 2005 | 13 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 1589 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2016 | 32848 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 621 | 0.050 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 21 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2004 | 644 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 6009 | 0.050 |
Why?
|
| Neurons | 2 | 2008 | 2287 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 106 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 111 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 323 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1582 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 38 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2005 | 1271 | 0.040 |
Why?
|
| Age Factors | 3 | 2018 | 5377 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 980 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 497 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 4109 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 2588 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 1163 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 276 | 0.040 |
Why?
|
| Cognition | 2 | 2015 | 968 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1021 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 17523 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 548 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 866 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 31252 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 80 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 163 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 249 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 71 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 756 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 226 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 215 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 316 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 597 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 30 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2013 | 225 | 0.030 |
Why?
|
| Carbidopa | 1 | 2011 | 17 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 4971 | 0.030 |
Why?
|
| Sensation | 1 | 2011 | 71 | 0.030 |
Why?
|
| Levodopa | 1 | 2011 | 92 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 59 | 0.020 |
Why?
|
| Disease Progression | 2 | 2014 | 6682 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1351 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 6100 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1945 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1900 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 154 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 160 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 899 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 471 | 0.020 |
Why?
|
| Brain | 3 | 2010 | 4113 | 0.020 |
Why?
|
| Attention | 1 | 2010 | 281 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 2139 | 0.020 |
Why?
|
| Pain | 1 | 2017 | 1658 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 275 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 14 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 1287 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 485 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7702 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 172 | 0.020 |
Why?
|
| Memory | 1 | 2010 | 429 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 873 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 882 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 5114 | 0.020 |
Why?
|
| Lewy Bodies | 1 | 2004 | 10 | 0.020 |
Why?
|
| Formates | 1 | 2004 | 8 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 220 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 108 | 0.020 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 4 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 51 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 94 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 2283 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 314 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 303 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 216 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 2170 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 702 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 1328 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 671 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 2086 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 4988 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 4892 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 164 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8865 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 2944 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 2927 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 1265 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 37905 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 4143 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 12873 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 5637 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 59536 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 2022 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 5710 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 7548 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 34495 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 21713 | 0.010 |
Why?
|